Top-Rated StocksTop-RatedNYSE:PHR Phreesia (PHR) Stock Price, News & Analysis → Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad) Free PHR Stock Alerts $23.16 +0.16 (+0.70%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$23.00▼$23.5150-Day Range$21.78▼$28.8752-Week Range$12.05▼$34.98Volume383,738 shsAverage Volume522,719 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$31.62 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Phreesia alerts: Email Address Phreesia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside36.5% Upside$31.62 Price TargetShort InterestHealthy3.83% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment-0.14Based on 22 Articles This WeekInsider TradingSelling Shares$1.88 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.48) to ($1.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector111th out of 914 stocksBusiness Services, Not Elsewhere Classified Industry20th out of 86 stocks 4.4 Analyst's Opinion Consensus RatingPhreesia has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoveragePhreesia has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.83% of the outstanding shares of Phreesia have been sold short.Short Interest Ratio / Days to CoverPhreesia has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Phreesia has recently decreased by 3.57%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPhreesia does not currently pay a dividend.Dividend GrowthPhreesia does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePhreesia has received a 60.31% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Patient flow management systems", "Health care management software", and "Personal health record software" products. See details.Environmental SustainabilityThe Environmental Impact score for Phreesia is -0.60. Previous Next 1.0 News and Social Media Coverage News SentimentPhreesia has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Phreesia this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for PHR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Phreesia to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phreesia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,884,749.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Phreesia is held by insiders.Percentage Held by Institutions92.10% of the stock of Phreesia is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phreesia are expected to grow in the coming year, from ($1.48) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phreesia is -9.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phreesia is -9.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhreesia has a P/B Ratio of 5.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceForget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.Click here to see the details. About Phreesia Stock (NYSE:PHR)Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.Read More PHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHR Stock News HeadlinesApril 13, 2024 | insidertrades.comJanet Gunzburg Sells 2,768 Shares of Phreesia, Inc. (NYSE:PHR) StockApril 11, 2024 | insidertrades.comPhreesia, Inc. (NYSE:PHR) Insider Sells $38,657.58 in StockApril 17, 2024 | InvestorPlace (Ad)Forget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.April 11, 2024 | insidertrades.comJanet Gunzburg Sells 2,817 Shares of Phreesia, Inc. (NYSE:PHR) StockMarch 28, 2024 | insidertrades.comPhreesia, Inc. (NYSE:PHR) CFO Sells $81,327.84 in StockMarch 26, 2024 | insidertrades.comPhreesia, Inc. (NYSE:PHR) COO Evan Roberts Sells 25,962 SharesApril 16, 2024 | americanbankingnews.comPhreesia, Inc. (NYSE:PHR) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 14, 2024 | americanbankingnews.comInsider Selling: Phreesia, Inc. (NYSE:PHR) Insider Sells 2,768 Shares of StockApril 17, 2024 | InvestorPlace (Ad)Forget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.April 12, 2024 | investing.comPhreesia Inc. general counsel sells over $233k in company stockApril 12, 2024 | investing.comPhreesia executive sells over $164,000 in company stockApril 12, 2024 | americanbankingnews.comChaim Indig Sells 12,043 Shares of Phreesia, Inc. (NYSE:PHR) StockApril 12, 2024 | americanbankingnews.comPhreesia, Inc. (NYSE:PHR) Insider Sells $65,551.59 in StockApril 12, 2024 | americanbankingnews.comPhreesia, Inc. (NYSE:PHR) General Counsel Sells $125,518.38 in StockApril 12, 2024 | americanbankingnews.comPhreesia, Inc. (NYSE:PHR) SVP Sells $75,867.48 in StockApril 12, 2024 | americanbankingnews.comJanet Gunzburg Sells 1,709 Shares of Phreesia, Inc. (NYSE:PHR) StockApril 12, 2024 | americanbankingnews.comEvan Roberts Sells 7,178 Shares of Phreesia, Inc. (NYSE:PHR) StockApril 12, 2024 | americanbankingnews.comBalaji Gandhi Sells 7,778 Shares of Phreesia, Inc. (NYSE:PHR) StockApril 9, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Phreesia (PHR)March 25, 2024 | finance.yahoo.comInsider Sell: COO Evan Roberts Sells 25,962 Shares of Phreesia Inc (PHR)March 23, 2024 | investing.comPhreesia executive sells over $700 in company stockMarch 22, 2024 | investing.comPhreesia Inc. SVP sells shares worth over $10,000March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Phreesia (PHR) and OmniAb (OABI)March 19, 2024 | finance.yahoo.comPhreesia Full Year 2024 Earnings: In Line With ExpectationsMarch 19, 2024 | msn.comPhreesia gets new technology chiefMarch 19, 2024 | businesswire.comPhreesia Announces Jack Callahan as New Chief Technology OfficerMarch 18, 2024 | msn.comStock Market News for Mar 18, 2024See More Headlines Receive PHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/17/2024Next Earnings (Estimated)5/29/2024Fiscal Year End1/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNYSE:PHR CUSIPN/A CIK1412408 Webwww.phreesia.com Phone(888) 654-7473Fax646-607-1776Employees1,438Year FoundedN/APrice Target and Rating Average Stock Price Target$31.62 High Stock Price Target$40.00 Low Stock Price Target$23.00 Potential Upside/Downside+36.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-136,880,000.00 Net Margins-38.42% Pretax Margin-37.99% Return on Equity-53.33% Return on Assets-38.04% Debt Debt-to-Equity Ratio0.02 Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$356.30 million Price / Sales3.67 Cash FlowN/A Price / Cash FlowN/A Book Value$4.52 per share Price / Book5.12Miscellaneous Outstanding Shares56,390,000Free Float53,117,000Market Cap$1.31 billion OptionableOptionable Beta0.92 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Chaim Indig (Age 45)Co-Founder, CEO & Director Comp: $515kMr. Evan Roberts (Age 45)Co-Founder & COO Comp: $400kMr. David Linetsky (Age 44)Senior Vice President of Life Sciences Comp: $551.64kMr. Balaji Gandhi (Age 50)Chief Financial Officer Ms. Janet M. Gunzburg (Age 58)VP, Principal Accounting Officer & Controller Mr. Jack CallahanChief Technology OfficerMs. Allison C. Hoffman (Age 53)General Counsel & Secretary Comp: $418.96kMs. Maureen McKinneyVice President of Corporate CommunicationsMs. Kharen HauckVice President of MarketingMs. Amy Beth VanDuyn (Age 51)Senior Vice President of Human Resources More ExecutivesKey CompetitorsMultiPlanNYSE:MPLNAutolus TherapeuticsNASDAQ:AUTLVerona PharmaNASDAQ:VRNAAdaptHealthNASDAQ:AHCODay One BiopharmaceuticalsNASDAQ:DAWNView All CompetitorsInsiders & InstitutionsWoodTrust Financial CorpBought 14,500 shares on 4/17/2024Ownership: 0.055%Chaim IndigSold 3,392 sharesTotal: $77,541.12 ($22.86/share)Evan RobertsSold 2,029 sharesTotal: $46,382.94 ($22.86/share)Allison C HoffmanSold 1,238 sharesTotal: $28,300.68 ($22.86/share)Amy Beth VanduynSold 685 sharesTotal: $15,659.10 ($22.86/share)View All Insider TransactionsView All Institutional Transactions PHR Stock Analysis - Frequently Asked Questions Should I buy or sell Phreesia stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHR shares. View PHR analyst ratings or view top-rated stocks. What is Phreesia's stock price target for 2024? 14 brokerages have issued 12 month price objectives for Phreesia's stock. Their PHR share price targets range from $23.00 to $40.00. On average, they predict the company's stock price to reach $31.62 in the next twelve months. This suggests a possible upside of 36.5% from the stock's current price. View analysts price targets for PHR or view top-rated stocks among Wall Street analysts. How have PHR shares performed in 2024? Phreesia's stock was trading at $23.15 on January 1st, 2024. Since then, PHR shares have increased by 0.0% and is now trading at $23.16. View the best growth stocks for 2024 here. When is Phreesia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 29th 2024. View our PHR earnings forecast. How were Phreesia's earnings last quarter? Phreesia, Inc. (NYSE:PHR) posted its earnings results on Thursday, March, 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.02. The company had revenue of $95 million for the quarter, compared to analysts' expectations of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative trailing twelve-month return on equity of 53.33%. The company's quarterly revenue was up 24.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.72) EPS. What ETFs hold Phreesia's stock? ETFs with the largest weight of Phreesia (NYSE:PHR) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Fidelity Disruptive Medicine ETF (FMED) and Jacob Forward ETF (JFWD).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Phreesia issued on next quarter's earnings? Phreesia issued an update on its FY 2025 earnings guidance on Thursday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $424.0 million-$434.0 million, compared to the consensus revenue estimate of $428.1 million. What is Chaim Indig's approval rating as Phreesia's CEO? 172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com. Chaim Indig has an approval rating of 73% among the company's employees. What other stocks do shareholders of Phreesia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Block (SQ), Appian (APPN), Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA). When did Phreesia IPO? Phreesia (PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray acted as the underwriters for the IPO. Who are Phreesia's major shareholders? Phreesia's stock is owned by a number of institutional and retail investors. Top institutional investors include Moody National Bank Trust Division (0.13%) and WoodTrust Financial Corp (0.05%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Chaim Indig, David Linetsky, Edward L Cahill, Evan Roberts, Gillian Munson, Janet Gunzburg, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub and Randy Rasmussen. View institutional ownership trends. How do I buy shares of Phreesia? Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:PHR) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchTop 5 AI Stocks to Buy for 2024Market Moving TrendsOptions trading has suddenly become more reliable.Eagle PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phreesia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.